Investing

Walgreen must face US lawsuit alleging false claims over hepatitis C drugs

Published

on

© Reuters. FILE PHOTO: Pigeons are seen resting on signage for Walgreens, owned by the Walgreens Boots Alliance, Inc., in Manhattan, New York City, U.S., November 26, 2021. REUTERS/Andrew Kelly/File Photo

(Reuters) – A federal appeals court on Tuesday revived a lawsuit by the United States and Virginia that accused Walgreens Boots Alliance (NASDAQ:) of misrepresenting that some patients met Virginia’s Medicaid-eligibility requirements for expensive hepatitis C drugs.

The 4th U.S. Circuit Court of Appeals said the governments plausibly alleged that Walgreen’s misrepresentations were material, and vacated a lower court ruling to the contrary.

Walgreen’s had been accused of violating the federal False Claims Act and Virginia state law.

Read the full article here

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version